Current depressed share price is due to Radient being delisted from the AMEX.
Current creditors have agreed to convert existing debt to equity which has also put downward pressure on the share price.
Radient's key product, Onku-Sure, is an F.D.A. approved and E.U. certified test for detecting colon/rectal cancer. Onku-Sure has the potential to generate $400,000,000 in sales in the United States alone. Company is a potential takeover target at multiples to the current share price.
There are any number of positive events that could substantially increase the share price 300-500%.
The following articles will provide you with a substantial amount of information about the upside potential that Radient's current share price offers.
Radient Pharmaceuticals' Onko-Sure(R) Is Proven Effective in Early Detection of Lung Cancer
No blood test is very effective for CRC screening (discussed many times in depth on this board for years). If there were evidence Radiant had one that even looked a little like it was, they wouldn't be struggling with their stock price. I don't know about their lung cancer performance, which seems to be their main thrust, perhaps there's value there.